FDA lifts holds on Epizyme, Sarepta programs

FDA lifted separate clinical holds on tazemetostat from Epizyme Inc. (NASDAQ:EPZM) and a gene therapy program targeting micro-dystrophin from Sarepta Therapeutics Inc. (NASDAQ:SRPT), the companies said Monday.

Epizyme is reopening enrollment in all of its U.S.

Read the full 353 word article

How to gain access

Continue reading with a
two-week free trial.